ArticleInternational journal of clinical oncology2026
Prevalence and prognostic impact of cancer cachexia in patients with bladder cancer: a multicenter retrospective study.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer cachexia is characterized by progressive skeletal muscle loss and systemic inflammation. Although sarcopenia is a known prognostic factor in bladder cancer, the prevalence and prognostic significance of cancer cachexia defined by standardized criteria remain unclear.
methodsWe retrospectively analyzed patients receiving first-line systemic chemotherapy for urothelial carcinoma at three institutions. Cancer cachexia was defined using the 2011 European Palliative Care Research Collaborative (EPCRC) criteria based on weight loss, body mass index, and CT-derived L3 skeletal muscle index. Patients were categorized by onset timing: no cachexia, baseline cachexia (pre-treatment), and acquired cachexia (developed during treatment). Survival outcomes and prognostic factors were analyzed using Kaplan-Meier methods, logistic regression, and Cox proportional hazards models.
resultsAmong 150 eligible patients, 45 (30.0%) had baseline cachexia, and 67 (44.7%) developed acquired cachexia during the observation period, resulting in a cumulative prevalence of 74.7%. Cachexia was significantly associated with advanced disease stage and sarcopenia. Overall survival (OS) significantly differed among the three groups (log-rank test, P = 0.005). The median OS was not reached in the no cachexia group, 836 days in the acquired cachexia group, and 742 days in the baseline cachexia group. Multivariable Cox analysis identified acquired cachexia, baseline cachexia and elevated C-reactive protein (CRP) (≥ 0.4 mg/dL) as independent predictors of poor OS.
conclusionCancer cachexia is highly prevalent in patients with bladder cancer receiving first-line chemotherapy and is independently associated with reduced survival, regardless of onset timing. Early identification may improve risk stratification and guide supportive interventions.
Indexed as
Identifiers
41999565What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.